MYC inhibition by Omomyc as a therapeutic strategy for (KRAS-mutated) colorectal cancer

被引：0
|
作者：
Kaur, J. [1 ]
Martinez-Martin, S. [2 ]
Foradada, L. [2 ]
Lopez-Estevez, S. [2 ]
Serrano, E. [1 ]
Martin-Fernandez, G. [1 ]
Thabussot, H. [3 ]
Cano, V. Castillo [3 ]
Casacuberta-Serra, S. [4 ]
Zacarias-Fluck, M. F. [1 ]
Grueso, J. [1 ]
Beaulieu, M. E. [5 ]
Whitfield, J. R.
Soucek, L. [1 ,5 ,6 ,7 ]
机构：
[1] Vall dHebron Inst Oncol, Models Canc Therapies Grp, Barcelona, Spain
[2] Peptomyc SL, Biomarkers, Barcelona, Spain
[3] Peptomyc SL, Prot Prod Platform, Barcelona, Spain
[4] Peptomyc SL, Immuno Oncol, Barcelona, Spain
[5] Peptomyc SL, Peptomyc, Barcelona, Spain
[6] Inst Catalana Recerca & Estudis Avancats, Icrea, Barcelona, Spain
[7] Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Bellaterra, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
68
引用
收藏
页码：S24 / S24
页数：1
相关论文
共 50 条
  • [21] Everolimus inhibits invasion and angiogenesis in a KRAS-mutated mesenchymal-differentiated colorectal cancer xenografts
    Tijeras-Raballand, Annemilai
    Dos Santos, Celia
    Serova, Maria
    Riveiro, Maria Eugenia
    de Gramont, Armand
    Faivre, Sandrine
    Raymond, Eric
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [22] KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
    Spindler, K. G.
    Appelt, A. L.
    Pallisgaard, N.
    Andersen, R. F.
    Jakobsen, A.
    BRITISH JOURNAL OF CANCER, 2013, 109 (12) : 3067 - 3072
  • [23] Japanese experience with hepatic resection of KRAS-mutated colorectal liver metastases
    Shindoh, Junichi
    CHINESE CLINICAL ONCOLOGY, 2019, 8 (05)
  • [24] Non-engineered T cells with specific anticancer effects in KRAS-mutated colorectal cancer
    Lim, Sunki
    Gho, Yujeong
    Kim, Seoyoung
    Kim, Min Ki
    Park, Jong Seob
    Lee, Wang Jun
    Lee, Young-Kwan
    Moon, Hyoun Jong
    CANCER RESEARCH, 2023, 83 (07)
  • [25] KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
    K G Spindler
    A L Appelt
    N Pallisgaard
    R F Andersen
    A Jakobsen
    British Journal of Cancer, 2013, 109 : 3067 - 3072
  • [26] MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers
    Choi, Yong Won
    Song, Young Soo
    Lee, Hyunwoo
    Yi, Kijong
    Kim, Young-Bae
    Suh, Kwang Wook
    Lee, Dakeun
    MEDICINE, 2016, 95 (15)
  • [27] Potential treatment target discovered for KRAS-mutated colon cancer
    不详
    COLORECTAL CANCER, 2012, 1 (02) : 100 - 100
  • [28] Comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
    Tougeron, D.
    Laurent-Puig, P.
    Zaanan, A.
    BRITISH JOURNAL OF CANCER, 2014, 111 (12) : 2379 - 2380
  • [29] Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer
    Toda, Kosuke
    Nishikawa, Gen
    Iwamoto, Masayoshi
    Itatani, Yoshiro
    Takahashi, Ryo
    Sakai, Yoshiharu
    Kawada, Kenji
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (08)
  • [30] Comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’
    D Tougeron
    P Laurent-Puig
    A Zaanan
    British Journal of Cancer, 2014, 111 : 2379 - 2380
12345